| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10003136 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10022107 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10026610 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10039904 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10036484 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10039557 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10018229 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10018230 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10018231 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
| TVIS10018232 | HBV | ENSG00000110092.4 | protein_coding | CCND1 | Yes | No | 595 | P24385 Q6FI00 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CCND1 |
|---|---|
| DrugBank ID | DB11718 |
| Drug Name | Encorafenib |
| Target ID | BE0001027 |
| UniProt ID | P24385 |
| Regulation Type | inhibitor |
| PubMed IDs | 26586345; 29573941 |
| Citations | Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao Y, Piao Y, Liu J, Cheng W, Bi X, Gong P, Song Z, Meng S: Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44. doi: 10.1016/j.canlet.2015.11.015. Epub 2015 Nov 14.@@Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpyrazoles |
| SMILES | COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C |
| Pathways | |
| PharmGKB | PA166179872 |
| ChEMBL | CHEMBL3301612 |
